GALE has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Galena Biopharma from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a report on Monday, November 7th. Maxim Group lowered shares of Galena Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, February 2nd. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Galena Biopharma has an average rating of “Hold” and an average price target of $3.47.
Galena Biopharma, Inc. (NASDAQ:GALE) – Equities research analysts at FBR & Co issued their FY2021 earnings per share (EPS) estimates for shares of Galena Biopharma in a research note issued on Monday. FBR & Co analyst V. Bernardino anticipates that the brokerage will post earnings per share of ($0.70) for the year. FBR & Co currently has a “Market Perform” rating and a $4.00 price objective on the stock.
Shares of Galena Biopharma (NASDAQ:GALE) traded down 1.4395% during midday trading on Tuesday, hitting $0.8216. 3,365,632 shares of the stock were exchanged. The stock’s market capitalization is $8.91 million. Galena Biopharma has a 1-year low of $0.82 and a 1-year high of $49.80. The firm’s 50 day moving average is $1.79 and its 200-day moving average is $1.17.
Galena Biopharma (NASDAQ:GALE) last issued its earnings results on Wednesday, November 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.03.
A hedge fund recently raised its stake in Galena Biopharma stock. Bank of New York Mellon Corp raised its position in Galena Biopharma, Inc. (NASDAQ:GALE) by 5.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 649,316 shares of the biotechnology company’s stock after buying an additional 32,290 shares during the period. Bank of New York Mellon Corp owned about 0.36% of Galena Biopharma worth $303,000 at the end of the most recent quarter.
About Galena Biopharma
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.